Heart failure & cardiomyopathies
Time to Clinical Benefit of Eplerenone Among Patients with Heart Failure and Reduced Ejection Fraction: A Subgroups Analysis from the EMPHASIS-HF Trial
Authors' conclusion
Eplerenone provides statistically significant and clinically meaningful benefits shortly after treatment initiation in most patients, irrespective of clinical profile.
Study context
- Population
- Patients with HF and a reduced ejection fraction (HFrEF) and mild symptoms
- Participants
- 2,737 patients
- Comparison
- Eplerenone vs placebo
- Primary endpoint
- Time to first significant reduction in CV death or first hospitalization for HF
Methodological detailsdouble-blind, subgroup analysis
- Double-blind
- Subgroup analysis
Primary result
As reported in the abstract
Day of first significant reduction in primary composite endpoint, by subgroup
- Heart failure (HF) history ≥18 months
- day 24
- eGFR <60 ml/min
- day 12
- Ischaemic HF aetiology
- day 28
- Age ≥65 years
- day 28
- Narrow QRS
- day 30
- Higher MAGGIC score
- day 35
- Lower potassium
- day 30
- LVEF ≥30%
- day 28
- Already treated with beta-blockers
- day 25
Further findings
Time to first significant reduction in primary composite endpoint (CV death or first HF hospitalisation), overall population · 26 days after randomisation
- Significant reduction in primary composite endpoint first observed 26 days after randomisation (HR 0.58; 95% CI 0.34-1.00)
- P = 0.049
Original publication
Time to Clinical Benefit of Eplerenone Among Patients with Heart Failure and Reduced Ejection Fraction: A Subgroups Analysis from the EMPHASIS-HF Trial. Eur J Heart Fail. Published 7 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →